ReST Therapeutics Inc
ReST Therapeutics is a clinical-stage biotech company dedicated to developing breakthrough therapies for neuropsychiatric disorders, including Alzheimer’s disease and Post-Traumatic Stress Disorder (PTSD). Their mission is to address unmet medical needs through precision medicine, with a focus on neuroprotection and neuroplasticity. They are advancing their flagship drug candidate FENM, which has shown promising preclinical results and is progressing through clinical development, including receiving endorsement from the European Medicine Agency (EMA) to enter First in Human trials.
Industries
Nr. of Employees
small (1-50)
ReST Therapeutics Inc
73 rue de Vaugirard, 75006 Paris, France
Patents
Use of fluoroethylnormemantine for the prevention and treatment of anxiety
US-11464751-B2
View DetailsChemical compounds derived from normemantine and use of same in the medical field
US-9714212-B2
View Details
Use of fluoroethylnormemantine for the prevention and treatment of anxiety
US-11464751-B2
View DetailsChemical compounds derived from normemantine and use of same in the medical field
US-9714212-B2
View DetailsProducts
Proprietary fluorinated NMDA receptor antagonist (lead clinical candidate)
A fluorinated small-molecule NMDA receptor channel inhibitor originally developed as an imaging biomarker and progressed as a therapeutic candidate for early intervention in stress-related disorders and neurodegenerative conditions; advanced through preclinical efficacy and safety studies and positioned for first-in-human administration.
Proprietary fluorinated NMDA receptor antagonist (lead clinical candidate)
A fluorinated small-molecule NMDA receptor channel inhibitor originally developed as an imaging biomarker and progressed as a therapeutic candidate for early intervention in stress-related disorders and neurodegenerative conditions; advanced through preclinical efficacy and safety studies and positioned for first-in-human administration.
Services
Partnership engagements with academic and clinical research groups to co-develop preclinical models, run behavioral and biochemical studies, and translate imaging biomarkers into therapeutic development.
Partnership engagements with academic and clinical research groups to co-develop preclinical models, run behavioral and biochemical studies, and translate imaging biomarkers into therapeutic development.
Expertise Areas
- NMDA receptor–targeted small-molecule therapeutics
- Preclinical behavioral neuroscience and pharmacology
- Translational biomarker development and PET-enabled compounds
- Preclinical electrophysiology and in vitro binding assays
Key Technologies
- Subtype-selective NMDA receptor channel inhibition
- Fluorinated small-molecule PET tracer chemistry
- Rodent behavioral assays (fear conditioning, forced swim, extinction learning)
- Radioligand binding assays
News & Updates
Dr. Tangui Maurice of Montpellier University and ReST’s scientific partner will present FENM results on Alzheimer during the upcoming 15th International Conference on Alzheimer’s and Parkinson’s Diseases.
FENM demonstrated anti-amnesic and neuroprotective effects in a pharmacological mouse model of Alzheimer’s disease, showing potential as a neuroprotective drug with superior efficacy to Memantine.
On October 11, 2022, the USPTO issued ReST Therapeutics a patent on the use of FENM for the treatment of anxiety and PTSD.
The European Medicine Agency endorsed ReST Therapeutics to enter First in Human clinical trials for FENM, supporting the development of a treatment for PTSD.
ReST Therapeutics and its academic co-owners received a patent from the INPI on neuroprotection, supporting their development of treatments for PTSD and Alzheimer’s.
Dr. Tangui Maurice of Montpellier University and ReST’s scientific partner will present FENM results on Alzheimer during the upcoming 15th International Conference on Alzheimer’s and Parkinson’s Diseases.
FENM demonstrated anti-amnesic and neuroprotective effects in a pharmacological mouse model of Alzheimer’s disease, showing potential as a neuroprotective drug with superior efficacy to Memantine.
On October 11, 2022, the USPTO issued ReST Therapeutics a patent on the use of FENM for the treatment of anxiety and PTSD.
The European Medicine Agency endorsed ReST Therapeutics to enter First in Human clinical trials for FENM, supporting the development of a treatment for PTSD.
ReST Therapeutics and its academic co-owners received a patent from the INPI on neuroprotection, supporting their development of treatments for PTSD and Alzheimer’s.